KIMBERLY CALDERON: Open Payments
NPI 1538681754 · MARSHALL, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,763 in 110 payments from 15 companies in 2025. Trend: 2023 $1,456 · 2024 $1,150 · 2025 $1,763
Food & beverage: $1,663Education: $100
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 18 | $288 |
| ABBVIE INC. | 20 | $278 |
| UCB, Inc. | 15 | $219 |
| Regeneron Healthcare Solutions, Inc. | 11 | $200 |
| Janssen Biotech, Inc. | 13 | $191 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 7 | $170 |
| Lilly USA, LLC | 10 | $146 |
| Novartis Pharmaceuticals Corporation | 4 | $59 |
| Kerecis Limited | 1 | $49 |
| Organon LLC | 5 | $44 |
Products named: DUPIXENT, Bimzelx, SKYRIZI, TREMFYA, TALTZ, RINVOQ, ILUMYA, Kerecis SurgiClose.
Industry payments across TX — which companies pay providers there.
